arrow
M

María José García

Universidad de Cantabria
H指数:22
被引数:1,814

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease

新诊断炎症性肠病患者生物制剂治疗、住院及手术的临床过程与预测因素:一项为期五年的前瞻性研究

2026-10-110
OA
Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease

JAK抑制剂对炎症性肠病患者肠道外表现和并发免疫介导性炎症性疾病的影响

2026-09-050
PRE
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

真实世界中乌帕替尼治疗克罗恩病的有效性与安全性:来自Eneida注册研究的启示

2026-04-300
OAAI
Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry

克罗恩病和溃疡性结肠炎患者中化脓性汗腺炎的发生情况:一项来自GETECCU-ENEIDA注册中心的全国多中心研究

2026-02-180
PRE
Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis

重症免疫检查点抑制剂诱导性结肠炎的临床、内镜及组织学特征

2026-01-030
OAAI
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

溃疡性结肠炎中JAK抑制剂的序贯治疗:同类别转换治疗的有效性与安全性

2025-11-030
PRE
Insights into the adoption of consensus guidelines for hyperkalemia management in Spain: a national, multicenter, descriptive analysis

关于西班牙高钾血症管理共识指南采纳情况的见解:一项全国性、多中心、描述性分析

2025-10-010
PRE
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU
2025-02-011
PRE
Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective study
2025-01-220
PRE
Multi-Omics Biomarkers for Predicting Therapeutic Efficacy in Inflammatory Bowel Disease: Advancing Towards Tailored Treatments
2025-01-220
PRE
Adherence to mesalazine suppositories maintenance treatment in patients with ulcerative proctitis: MESUPO multicenter prospective observational study from GETECCU
2025-01-220
PRE
Feasibility and safety of endoscopic submucosal dissection in inflammatory bowel disease (ESDEUR-IBD): an interim analysis of European retrospective study
2025-01-220
PRE
Identification of metabolic predictive biomarkers of response to Inflammatory Bowel Disease treatment
2025-01-220
PRE
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
2024-11-011
PRE
Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases
2024-10-010
OAAI
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
2024-07-092
OA